In this week’s edition of InnovationRx, we look at a former Wall Street analyst’s $4 billion obesity drug company, Wegovy’s weight-loss pill, and more.
Expert physician, Dr. Aly Cohen, explains ways to limit our exposure to toxins in our daily life.
A new mRNA-based method reprograms immune cells directly inside solid tumors, boosting anti-cancer activity and paving the way for next-generation therapies.
From “pajama time” spent responding to patient messages to debates over internet misinformation, here is why your doctor is exhausted and how it impacts your longevity.
James Clear explains on the Huberman Lab podcast why habits stick through systems, identity and environment rather than sheer willpower.
Convenience of an oral pill may be critical to some patients. This could expand the market but also improve patient persistence and sustainability of long-term outcomes.
In high school, Kat Cole was a Hooters girl. She’s now the CEO of a billion-dollar company, AG1. Here, she weighs in on wellness in 2026, Ozempic, and Burning Man.
A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the future of genetic medicine and patient care.
The abrupt revision of the U.S. childhood vaccine schedule from 17 vaccines to 11. belies promises to the American people that access to vaccines would not be affected.
With major NIH cuts under Trump, here are initiatives in states like New York, California and Massachusetts to get state governments to support more scientific research.